Autoselection technology for microbial evolution
Raised to date
$50K
of $750K offered across 1 Form D filing
Selva Nexus builds proprietary autoselection technology for microbial evolution. Its platform automates the selection step of microbial R&D, aiming to close the loop between a hypothesis and a production-ready strain. The company is based in Albuquerque, New Mexico and was founded by three co-founders spanning biology, engineering and operations.
Patent-pending autoselection technology that automates the selection step of microbial strain optimization, which is otherwise slow and labor-intensive.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 23, 2026 | Equity | $50K/ $750K | Form D |
Biotech research platform
A proprietary, closed-loop platform that automates selection in microbial evolution, iterating biological optimization from hypothesis to production-ready strain.
Built for
Teams using microbes for protein expression, cell or phage therapeutics, waste breakdown and other industrial or research tasks